NCT04375228View on ClinicalTrials.gov

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Immune-related Adverse EventsAdvanced Solid Tumor
Interventions
DRUG

Rituximab

375mg/m\^2 IV weekly for 4 doses

DRUG

Tocilizumab

4mg/kg IV once a month for up to 2 doses

Trial Locations (3)

10022

Memorial Sloan Kettering Cancer Center, New York

10032

Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York

21224

Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Columbia University

OTHER